Fuso Pharmaceutical Industries Ltd.

Ōsaka, Japan

Fuso Pharmaceutical Industries Ltd.

Ōsaka, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Tohoku University, Gunma University and Fuso Pharmaceutical Industries Ltd. | Date: 2017-01-04

The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula:^(1), R^(2), R^(3), R^(4), R^(5), R^(6), R^(7), m, n, p, X, and Y are as defined in the specification, or a pharmaceutically acceptable salt thereof.


Patent
University of Miyazaki and Fuso Pharmaceutical Industries Ltd. | Date: 2017-03-22

The present invention provides a heparin which does not substantially contain a nitrous acid degradation-resistant impurity, wherein, with respect to the peak total area value detected by refractive index (RI) which appears at the elution point of the heparin obtained when a reference heparin is analyzed by high performance liquid chromatography (HPLC), the peak total area value which appears at the elution point of the heparin which has been degraded with the above nitrous acid and analyzed by HPLC under the same conditions, is 5% or less,wherein the analysis is conducted by high performance liquid chromatography (HPLC) under the conditions disclosed in the Molecular Weight section in the Parnaparin sodium Standard Test Method described in The Japanese Pharmacopoeia, fifteenth edition.


Patent
Fuso Pharmaceutical Industries Ltd. | Date: 2015-01-29

Very simple, highly sensitive detection or quantification of target nucleic acids of interest has been achieved by: hybridizing mask oligonucleotides to regions in a single-stranded region of a nucleic acid to be assayed between which a region to be hybridized by an oligonucleotide probe is positioned, thereby opening the probe-hybridizing region and keeping the single-stranded region of the target nucleic acid stable, and then subjecting this nucleic acid having the single-stranded region to nucleic acid chromatography.


Patent
Taisei Kako Co., Fuso Pharmaceutical Industries Ltd. and Matrix | Date: 2016-07-13

A syringe and a syringe set are provided. The syringe can be readily distinguished from other syringes only by viewing a tip of the syringe. The syringe includes a tip 15 provided at an end of a barrel body 11 to be filled with a medicine and having an outer diameter of 4.315 mm to 6 mm, a peripheral wall 18 provided around the tip 15 concentrically with the tip 15, and a helical rib 19 formed on an inner face of the peripheral wall 18 or an outer face of the tip 15.


Patent
Tohoku University, Gunma University and Fuso Pharmaceutical Industries Ltd. | Date: 2016-01-13

Disclosed herein is an osteopontin production inhibitor capable of preventing a disease resulting from increased production of osteopontin. The osteopontin production inhibitor contains a dictyopyrone derivative or a dihydrodictyopyrone derivative as an active ingredient. The dictyopyrone derivative is preferably a compound represented by Chemical Formula 1 or 2, and the dihydrodictyopyrone derivative is preferably a compound represented by Chemical Formula 3 or 4.


Patent
Fuso Pharmaceutical Industries Ltd. and Nextier | Date: 2016-06-15

An airway is secured without obstructing sleep even when the lingual radix falls into the airway. An airway expansion apparatus (1) is configured to include a pillow portion (2) that supports a cranial portion, a pair of left and right mandible holding portions (3) that hold the mandible coupled to the cranial portion at the temporomandibular joint, a first actuation mechanism (4) that causes the mandible holding portions to come into contact with the mandible, and a second actuation mechanism (5) that lifts the mandible holding portions with respect to the pillow portion with the mandible holding portions kept in contact with the mandible, in which the mandible is kept lifted.


Patent
Fuso Pharmaceutical Industries Ltd. | Date: 2016-09-21

A novel highly stable sodium diacetate crystal, in which the volatilization of acetic acid can be suppressed for a long period. More specifically, a sodium diacetate crystal having a median diameter in the range of 300 to 3000 m.


Patent
Tohoku University, Gunma University and Fuso Pharmaceutical Industries Ltd. | Date: 2015-02-27

The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula: wherein R^(1), R^(2), R^(3), R^(4), R^(5), R^(6), R^(7), m, n, p, X, and Y are as defined in the specification, a pharmaceutically acceptable salt thereof.


Patent
Fuso Pharmaceutical Industries Ltd. | Date: 2016-12-14

Very simple, highly sensitive detection or quantification of target nucleic acids of interest has been achieved by: hybridizing mask oligonucleotides to regions in a single-stranded region of a nucleic acid to be assayed between which a region to be hybridized by an oligonucleotide probe is positioned, thereby opening the probe-hybridizing region and keeping the single-stranded region of the target nucleic acid stable, and then subjecting this nucleic acid having the single-stranded region to nucleic acid chromatography.


Patent
Kinki University and Fuso Pharmaceutical Industries Ltd. | Date: 2016-03-30

The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action. (In formula (1), each of R^(1) and R^(2) independently represents H, -OH or -OR^(11), wherein R^(11) represents a C_(1-3) alkyl group; each of R^(3) and R^(4) independently represents H, -OH or -OR^(12), wherein R^(12) represents a C_(1-3) alkyl group; and each of R^(5) and R^(6) independently represents H, a halogen atom, a C_(1-10) alkyl group, a C_(2-6) alkenyl group, a C_(2-6) alkynyl group, a phenyl group (which may be substituted by a C_(1-6) alkoxy group or a halogen atom), a -C_(1-3) alkyl-phenyl group (which may be substituted by a C_(1-6) alkyloxy group or a halogen atom) or a C_(10-50) prenyl group.)

Loading Fuso Pharmaceutical Industries Ltd. collaborators
Loading Fuso Pharmaceutical Industries Ltd. collaborators